Trials / Terminated
TerminatedNCT06287463
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Deciphera Pharmaceuticals, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).
Conditions
- Advanced Solid Tumor
- RAF Mutation
- RAS Mutation
- NF1 Mutation
- Non-Small Cell Lung Cancer
- Pancreatic Ductal Adenocarcinoma
- Melanoma
- BRAF Gene Mutation
- CRAF Gene Mutation
- Castration-Resistant Prostate Cancer (CRPC)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DCC-3084 | Administered orally |
Timeline
- Start date
- 2024-05-14
- Primary completion
- 2026-02-13
- Completion
- 2026-02-13
- First posted
- 2024-03-01
- Last updated
- 2026-03-05
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06287463. Inclusion in this directory is not an endorsement.